NasdaqCM - Nasdaq Real Time Price USD

Adial Pharmaceuticals, Inc. (ADIL)

1.2295 -0.0305 (-2.42%)
As of 1:14 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
6,464.1940
--
10,859.4750
17,740.3260
10,927.9850
8,244.9000
Operating Income
-6,464.1940
--
-10,859.4750
-17,740.3260
-10,927.9850
-8,244.9000
Net Non Operating Interest Income Expense
63.6880
--
63.3380
6.5390
32.4950
95.2340
Other Income Expense
-1,297.3830
--
522.0000
-1,783.6160
2.5000
-441.7630
Pretax Income
-11,238.5670
--
-10,796.1370
-19,517.4030
-10,892.9900
-8,591.4290
Tax Provision
--
--
--
-94.0770
--
--
Net Income Common Stockholders
-8,694.0650
--
-12,731.4160
-19,423.3260
-10,892.9900
-8,591.4290
Diluted NI Available to Com Stockholders
-8,694.0650
--
-12,731.4160
-19,423.3260
-10,892.9900
-8,591.4290
Basic EPS
-3.04
-3.60
-12.71
-26.00
-21.75
--
Diluted EPS
-3.04
-3.60
-12.71
-26.00
-21.75
--
Basic Average Shares
1,898.5040
1,424.6610
1,001.5050
743.5490
498.5250
--
Diluted Average Shares
1,898.5040
1,424.6610
1,001.5050
743.5490
498.5250
--
Total Operating Income as Reported
-6,464.1940
--
-10,859.4750
-19,288.7230
-10,927.9850
-8,244.9000
Total Expenses
6,464.1940
--
10,859.4750
17,740.3260
10,927.9850
8,244.9000
Net Income from Continuing & Discontinued Operation
-8,694.0650
--
-12,731.4160
-19,423.3260
-10,892.9900
-8,591.4290
Normalized Income
-6,774.1400
--
-10,796.1370
-17,602.0005
-10,892.9900
-8,149.6660
Interest Income
63.6880
--
63.3380
6.5390
32.4950
95.2340
Net Interest Income
63.6880
--
63.3380
6.5390
32.4950
95.2340
EBIT
-6,464.1940
--
-10,859.4750
-17,740.3260
-10,927.9850
-8,244.9000
EBITDA
-6,463.6300
--
-10,858.9110
-17,685.2200
-10,927.4210
-8,244.3350
Reconciled Depreciation
0.5640
--
0.5640
55.1060
0.5640
0.5650
Net Income from Continuing Operation Net Minority Interest
-11,238.5670
--
-10,796.1370
-19,423.3260
-10,892.9900
-8,591.4290
Total Unusual Items Excluding Goodwill
-4,464.4270
--
522.0000
-1,830.1100
--
-441.7630
Total Unusual Items
-4,464.4270
--
522.0000
-1,830.1100
--
-441.7630
Normalized EBITDA
-1,999.2030
--
-10,858.9110
-15,855.1100
-10,927.4210
-7,802.5720
Tax Rate for Calcs
--
--
--
0.0000
--
--
Tax Effect of Unusual Items
--
--
--
-8.7845
--
--
12/31/2019 - 7/27/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SPRC SciSparc Ltd.
0.9001
-4.47%
 
ZVSA ZyVersa Therapeutics, Inc.
4.7275
-0.26%
 
ALLR Allarity Therapeutics, Inc.
0.5100
-8.08%
 
BNOX Bionomics Limited
0.7100
+0.71%
 
CERO CERo Therapeutics Holdings, Inc.
0.6800
-9.85%
 
CYCC Cyclacel Pharmaceuticals, Inc.
2.0200
+2.02%
 
FGEN FibroGen, Inc.
1.1296
-5.08%
 
MBIO Mustang Bio, Inc.
0.1470
-5.16%
 
KTRA Kintara Therapeutics, Inc.
0.2200
-14.33%
 
FRES Fresh2 Group Limited
0.4200
-9.68%